HMG-COA REDUCTASE INHIBITORS (STATINS) ASSOCIATED TENDON RUPTURE: AN ANALYSIS OF REPORTS FROM THE FOOD AND DRUG ADMINISTRATION'S ADVERSE REPORTING SYSTEM

被引：0
|
作者：
Rafi, J. A. [1 ]
Arabyat, R. [1 ]
Chen, C. [1 ]
Raisch, D. W. [1 ]
机构：
[1] Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.066
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV1
引用
收藏
页码：A39 / A39
页数：1
相关论文
共 50 条
  • [1] Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Benoit Chauvin
    Sylvain Drouot
    Aurélie Barrail-Tran
    Anne-Marie Taburet
    Clinical Pharmacokinetics, 2013, 52 : 815 - 831
  • [2] Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system
    Arabyat, Rasha M.
    Raisch, Dennis W.
    McKoy, June M.
    Bennett, Charles L.
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (11) : 1653 - 1660
  • [3] Drug-Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors
    Chauvin, Benoit
    Drouot, Sylvain
    Barrail-Tran, Aurelie
    Taburet, Anne-Marie
    CLINICAL PHARMACOKINETICS, 2013, 52 (10) : 815 - 831
  • [4] FLUOROQUINOLONE- ASSOCIATED TENDON-RUPTURE: A SUMMARY OF REPORTS IN THE FOOD AND DRUG ADMINISTRATION'S (FDA'S) ADVERSE EVENT REPORTING SYSTEM
    Arabyat, R. M.
    Garg, V
    Raisch, D. W.
    Bennett, C.
    VALUE IN HEALTH, 2013, 16 (03) : A217 - A217
  • [5] HMG-CoA reductase inhibitors (statins) and bone mineral density: A meta-analysis
    Liu, Jie
    Zhu, Li-Ping
    Yang, Xu-Li
    Huang, He-Lang
    Ye, Dong-Qing
    BONE, 2013, 54 (01) : 151 - 156
  • [6] Drug interactions with HMG-CoA reductase inhibitors (statins): The importance of CYP enzymes, transporters and pharmacogenetics
    Neuvonen, Pertti J.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (03) : 323 - 332
  • [7] HMG-CoA reductase inhibitors (statins) and acute kidney injury: A secondary analysis of renal study outcomes
    Wang, Amanda Y.
    Trongtrakul, Konlawij
    Bellomo, Rinaldo
    Li, Qiang
    Cass, Alan
    Gallagher, Martin
    NEPHROLOGY, 2019, 24 (09) : 912 - 918
  • [8] HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival
    Younas, Nizar
    Wu, Christine M.
    Shapiro, Ron
    McCauley, Jerry
    Johnston, James
    Tan, Henkie
    Basu, Amit
    Schaefer, Heidi
    Smetanka, Cynthia
    Winkelmayer, Wolfgang C.
    Unruh, Mark
    BMC NEPHROLOGY, 2010, 11
  • [9] HMG-CoA reductase inhibitors in kidney transplant recipients receiving tacrolimus: statins not associated with improved patient or graft survival
    Nizar Younas
    Christine M Wu
    Ron Shapiro
    Jerry McCauley
    James Johnston
    Henkie Tan
    Amit Basu
    Heidi Schaefer
    Cynthia Smetanka
    Wolfgang C Winkelmayer
    Mark Unruh
    BMC Nephrology, 11
  • [10] Dalfampridine Associated Serious Adverse Events: An Analysis of Data from the Food and Drug Administration's Adverse Event Reporting System
    Ahmed, Nehad J.
    Alahmari, Abdullah K.
    Alshehri, Ahmed M.
    Almalki, Ziyad S.
    LATIN AMERICAN JOURNAL OF PHARMACY, 2022, 41 (06): : 1195 - 1199
12345